Page 127 - Libro Memoria Cien Inglés
P. 127
collaborations between Centers of Ex- among brain disorders suggests sha-
cellence, the projects will also serve to red pathogenic mechanisms. In parti-
provide a platform for future collabora- cular, hyperexcitable states driven by
tion with the industry glial activation and neuroinflammation
appear almost ubiquitous in these
disorders. With advances in unders-
OTHER INTERNATIONAL ACTIVI- tanding the function of the purinergic
TIES ionotropic P2X7 receptor (P2X7R), the
highly promising effects demonstrated
H2020 MARIE SKŁODOWSKA-CURIE by its antagonists in models of brain
ACTIONS: INNOVATIVE TRAINING NE- disease, and the large investment in
TWORKS
P2X7R-related drug development pro-
The Innovative Training Networks (ITN) grams, now is the perfect time to pool
are actions created by the European resources. Studying these mechanisms
Union (within the Horizon 2020 pro- offers the potential to improve symp-
gram framework) to support research toms and reverse disease progression
in the European Research Area and in a wide range of brain disorders.
are aimed to form, through an inter- Through its role in regulating neuroin-
national network of public and private flammation and the mechanistic link
centers, a new generation of creative between neuronal hyperexcitability
and innovative researchers, capable and glial activation, P2X7R with ATP is
of transforming knowledge and ideas one of the most promising molecular
into products and services for the targets for pharmacological interven-
economic and social benefit of the tion in the neuroinflammation-hype-
European Union. The CIEN Founda- rexcitability pathway. PurinesDX brings
tion actively participates as Associated together world leaders in translational
Partner in the following ITN: research on purinergic signaling, lea-
ding European clinical specialists in a
Targeting the purinergic P2X7 receptor wide range of neurological diseases
to treat Alzheimer’s disease and industry partners specialized in
drug and biomarker development. The
Brain disorders affect some 180 million ability to share unique genetic tools,
people and their families in Europe newly developed diagnostic devices
alone, with an annual cost to the ta- and novel, selective and stable P2X7R
xpayer estimated at 800 billion €, an antagonists in the brain, along with
economic burden greater than cardio- the synergy facilitated by the Purines-
vascular disease and cancer combined. DX consortium will be extended to the
Despite diverse etiologies, the overlap training of a new generation of highly
in clinical symptoms and comorbidities
skilled, innovative scientists, creative
